Corporate Banner
Satellite Banner
Crystallography
Scientific Community
 
Become a Member | Sign in
Home>Events>This Event
  Events - February 2014


Advances and Progress in Drug Design

17 Feb 2014 - 18 Feb 2014 - London, UK



Bookmark and Share


SPONSORED BY CHEMICAL COMPUTING GROUP

SMi are proud to present the 13th annual Advances and Progress in Drug Design conference, convening in Central London on Monday 17 and Tuesday 18 February 2014. This exciting event will focus on new approaches and will offer attendees the chance to hear from leading industry experts on lead optimisation strategies, SBDD and FBDD. 

Past events have received positive feedback from the industry including ‘Well selected talks, stimulating atmosphere’ – Sanofi, ‘Very good interactive meeting, overall excellent’ – Pfizer and ‘a very good meeting – right number of people’ - AstraZeneca

Advances and Progress in Drug Design Conference will build on the success of our previous events and bring together a unique mix of senior executives from all over industry and academia and will be an unrivalled forum for problem-solving discussion and debate. 

Benefits of Attending:

Understand pharma's current and future drug design strategies and highlight the challenges the industry is currently facing

Explore the latest approaches in structure-based drug design

Evaluate lead optimisation strategies

Consider the latest in fragment based drug discovery as the future of drug design

Linking HTS and FBDD - examining alternative approaches in drug discovery

Participate in two post conference interactive workshops hosted by Vernalis on New Approaches in ‘Structure Based Design’, and the 2nd hosted by The Research Network on ‘Chemically Modified Biologicals’

Ample opportunity for peer to peer networking with two morning coffee breaks, two networking lunches, two afternoon tea sessions and a networking drinks reception hosted by Chemical Computing Group on end of day one.

Key Speakers for 2014

John Mathias, Head of Medicinal Chemistry - Inflammation & Remodelling, Pfizer

Sudharsan Sridharan, Scientist, MedImmune

Tom Heightman, Senior Director, Astex Pharmaceuticals

Amaury Ernesto Fernandez-Montalvan, Lab Head, High Throughput Screening, Bayer HealthCare Pharmaceuticals

Karl-Heinz Baringhaus, Head of R&D, Sanofi-Aventis

Andreas Kuglstatter, Head of Protein Crystallography, Roche Chemische Unternehmungen AG

Dr Neil Press, Director, Novartis

Paul Labute, CEO, Chemical Computing Group

Andrea Bortolato, Senior Computational Chemistry, Heptares Therapeutics

Paul Brennan, Group Head/PI, Nuffield Department of Medicine

For further information visit us online at www.drug-design.co.uk

Alternatively, contact John Collins on +44 (0)20 7827 6734 or email jcollins@smi-online.co.uk




Further information
Scientific News
Human Astrovirus Structure Could Lead to Therapies, Vaccines
Study shows where neutralizing antibody binds to human astrovirus, a leading cause of viral diarrhoea in children, elderly, and the immune-compromised.
Drug Design Strategy to Improve Breast Cancer Treatment
Scientists develop novel structure-based drug design strategy aimed at altering the basic landscape of hormone-driven breast cancer treatment.
Crystals, Super Magnets in Drug Discovery
Scientists have produced larger superparamagnetic crystals that could revolutionise drug delivery.
Peer Review is in Crisis, But Should be Fixed, Not Abolished
After the time to get the science done, peer review has become the slowest step in the process of sharing studies, and some scientists have had enough.
Snapshots of Chemical Flipping a Biological Switch
X-ray laser gets first real-time snapshots of a chemical flipping a biological switch, opening new path to understanding how RNA works.
Uncovering Elusive Proteins
Researchers have determined the complete structure of elusive proteins, known as tetraspanins, for the first time.
Cannabinoid Receptor Structure Revealed
Scientists provided a detailed view of the primary molecule through which cannabinoids exert their effects on the brain. The findings might help guide the design of more targeted medicines with fewer side effects.
Alzheimer’s Treatment Moves a Step Closer
Merck scientists have reported the discovery of verubecestat, a structurally unique, orally bioavailable small molecule that has been shown to target the most visible sign of the disease in the brain.
Study Unocovers Cancer-Linked Protein’s Associates
Researchers have developed a new list of nearly 100 potential partners of a cancer-linked enzyme by studying its interactions with other proteins.
Scientists Uncover Why Hepatitis C Vaccine is Difficult to Make
Scientists have uncovered one reason why a successful hepatitis C vaccine continues to be elusive.
Scroll Up
Scroll Down
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,300+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!